PYC Therapeutics Meets Kidney Disease Trial Enrolment Target
PYC: $1.84 -4.18% · MC: $1.9B
PYC Therapeutics has met its interim enrolment target of 24 patients in the Phase 1b repeat-dose study of PYC-003 for polycystic kidney disease and will continue recruiting. The company aims to report kidney volume data for at least 24 patients in calendar 2027 and progress to a potentially registrational Phase 2/3 trial in 2028, subject to regulatory alignment and patient dropout assumptions. It also expects to present data from the ongoing study and its open-label extension in 2027.

Comments